The Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Mouse Colon Tumorigenesis in Type 2 Diabetes Mice

被引：0
|
作者：
Yorifuji, Naoki
Inoue, Takuya
Fujiwara, Kaori
Iguchi, Munetaka
Kojima, Yuichi
Okada, Toshihiko
Kakimoto, Kazuki
Nouda, Sadaharu
Kawakami, Ken
Abe, Yosuke
Takeuchi, Toshihisa
Higuchi, Kazuhide
机构：
来源：
GASTROENTEROLOGY | 2015年 / 148卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Su2023
引用
收藏
页码：S577 / S577
页数：1
相关论文
共 50 条
  • [21] Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Decreases Systolic Blood Pressure in Japanese Hypertensive Patients with Type 2 Diabetes
    Ogawa, Susumu
    Ishiki, Mikihito
    Nako, Kazuhiro
    Okamura, Masashi
    Senda, Miho
    Mori, Takefumi
    Ito, Sadayoshi
    TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, 2011, 223 (02): : 133 - 135
  • [22] Saxagliptin: A dipeptidyl peptidase-4 inhibitor in the treatment of type 2 diabetes mellitus
    Dave, Darshan J.
    JOURNAL OF PHARMACOLOGY & PHARMACOTHERAPEUTICS, 2011, 2 (04) : 230 - 235
  • [23] Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes
    Scott, R.
    Wu, M.
    Sanchez, M.
    Stein, P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (01) : 171 - 180
  • [24] Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Deacon, Carolyn F.
    Holst, Jens J.
    ADVANCES IN THERAPY, 2009, 26 (05) : 488 - 499
  • [25] Linagliptin: The Newest Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Aletti, Rachael
    Cheng-Lai, Angela
    CARDIOLOGY IN REVIEW, 2012, 20 (01) : 45 - 51
  • [26] Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Tatosian, Daniel A.
    Guo, Ying
    Schaeffer, Andrea K.
    Gaibu, Natalia
    Popa, Serghei
    Stoch, Aubrey
    Langdon, Ronald B.
    Kauh, Eunkyung A.
    DIABETES THERAPY, 2013, 4 (02) : 431 - 442
  • [27] Dipeptidyl Peptidase-4 Inhibition in Patients with Type 2 Diabetes Treated with Saxagliptin, Sitagliptin, or Vildagliptin
    Daniel A. Tatosian
    Ying Guo
    Andrea K. Schaeffer
    Natalia Gaibu
    Serghei Popa
    Aubrey Stoch
    Ronald B. Langdon
    Eunkyung A. Kauh
    Diabetes Therapy, 2013, 4 : 431 - 442
  • [28] Saxagliptin: A dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes mellitus
    Neumiller, Joshua J.
    Campbell, R. Keith
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2010, 67 (18) : 1515 - 1525
  • [29] Long-Term Treatment With a Dipeptidyl Peptidase-4 Inhibitor, Sitagliptin, Suppresses Intestinal Tumors in Models of Diabetes and Obesity
    Fujiwara, Kaori
    Yorifuji, Naoki
    Nouda, Sadaharu
    Kakimoto, Kazuki
    Okada, Toshihiko
    Kawakami, Ken
    Takeuchi, Toshihisa
    Inoue, Takuya
    Higuchi, Kazuhide
    GASTROENTEROLOGY, 2016, 150 (04) : S591 - S591
  • [30] Alogliptin: A New Dipeptidyl Peptidase-4 Inhibitor for Type 2 Diabetes Mellitus
    Jarvis, Courtney I.
    Cabrera, Adriana
    Charron, Derek
    ANNALS OF PHARMACOTHERAPY, 2013, 47 (11) : 1532 - 1539
12345